Enzene Biosciences, based out of Pune in India, has announced the launch of ranibizumab, a biosimilar to Lucentis, which is sold under the name Accentrix in India.^1-3

The ranibizumab biosimilar is a recombinant antigen-binding fragment (Fab) that is used in therapy for neovascular age-related macular degeneration (AMD). It is also the company’s 7th biosimilar following the launch of Bevacizumab for the treatment of metastatic colorectal cancer.^1-3

The biosimilar showed comparative clinical efficacy to Lucentis in phase 3 clincial studies and is produced using the company’s “state-of-the-art MAR system” at its plant in Chakan, Pune.¹

Himanshu Gadgil, PhD, CEO, Enzene Biosciences said, “Prior to Ranibizumab, our teams have successfully delivered 6 commercial biosimilars and supported our partners with clinical supplies of novel biologic entities (NBE’s), such as monoclonal antibodies (mAbs) and multi-specific molecules."¹

Enzene’s Ranibizumab matches competitors in terms of product purity and is designed to bind and inhibit vascular endothelial growth factor (VEGF-A), thereby interrupting the interaction of VEGF with its receptors.¹

Enzene is actively progressing with the development of 3 additional biosimilars in various stages and plans to expand into markets like the USA soon.

References:

1. Enzene Biosciences launches Ranibizumab as affordable alternative to treat neovascular AMD. Accessed November 30, 2023. https://www.biospectrumindia.com/news/73/23883/enzene-biosciences-launches-ranibizumab-as-affordable-alternative-to-treat-neovascular-amd.html

2. Enzene biosciences launches Ranibizumab to treat neovascular AMD. Accessed November 30, 2023. https://health.economictimes.indiatimes.com/news/pharma/pharma-industry/enzene-biosciences-launches-ranibizumab-to-treat-neovascular-amd/105478892

3. Enzene Biosciences Unveils Cost-Efficient Biosimilar, Ranibizumab For Macular Degeneration Treatment. Accessed November 30, 2023. https://bwhealthcareworld.businessworld.in/article/Enzene-Biosciences-Unveils-Cost-Efficient-Biosimilar-Ranibizumab-For-Macular-Degeneration-Treatment/26-11-2023-500084/

Source:- Ophthalmology